Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Amazon Explores AI Content Marketplace With Media Publishers 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
SALT LAKE CITY, Dec. 19, 2017 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the JP Morgan Annual Healthcare Conference at 2:00 p.m. PT on January 8, 2018, in San Francisco, California.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five strategic imperatives: stabilizing hereditary cancer revenue, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Media Contact:
Ron Rogers
(801) 584-3065
[email protected]
Investor Contact:
Scott Gleason
(801) 584-1143
[email protected]
